Connection

Co-Authors

This is a "connection" page, showing publications co-authored by DIANE C BODURKA and LOIS M RAMONDETTA.
Connection Strength

1.789
  1. Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. Support Care Cancer. 2017 06; 25(6):1985-1991.
    View in: PubMed
    Score: 0.146
  2. Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. Gynecol Oncol. 2016 09; 142(3):525-30.
    View in: PubMed
    Score: 0.140
  3. Dying well: How equal is end of life care among gynecologic oncology patients? Gynecol Oncol. 2016 Feb; 140(2):295-300.
    View in: PubMed
    Score: 0.135
  4. Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. Gynecol Oncol. 2015 Dec; 139(3):553-8.
    View in: PubMed
    Score: 0.133
  5. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. Gynecol Oncol. 2015 Aug; 138(2):388-93.
    View in: PubMed
    Score: 0.129
  6. Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer. 2015 Jul; 23(7):2025-32.
    View in: PubMed
    Score: 0.126
  7. Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. Gynecol Oncol. 2014 Nov; 135(2):244-8.
    View in: PubMed
    Score: 0.123
  8. Ethics consultation on a gynecologic oncology service: an opportunity for physician education. J Cancer Educ. 2011 Mar; 26(1):183-7.
    View in: PubMed
    Score: 0.097
  9. Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int J Gynecol Cancer. 2004 Jul-Aug; 14(4):580-8.
    View in: PubMed
    Score: 0.061
  10. Mentorship and productivity among gynecologic oncology fellows. J Cancer Educ. 2003; 18(1):15-9.
    View in: PubMed
    Score: 0.055
  11. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol. 2001 Jul; 82(1):156-61.
    View in: PubMed
    Score: 0.049
  12. Survey of female gynecologic oncologists and fellows: balancing professional and personal life. Gynecol Oncol. 2000 Nov; 79(2):309-14.
    View in: PubMed
    Score: 0.047
  13. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
    View in: PubMed
    Score: 0.047
  14. How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. Gynecol Oncol. 2019 03; 152(3):452-458.
    View in: PubMed
    Score: 0.042
  15. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018 06; 149(3):484-490.
    View in: PubMed
    Score: 0.039
  16. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018 01; 131(1):109-116.
    View in: PubMed
    Score: 0.039
  17. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. Int J Gynecol Cancer. 2017 09; 27(7):1350-1359.
    View in: PubMed
    Score: 0.038
  18. The Advance Care Planning Readiness Scale: Development and Validation of a Measure of Willingness to Discuss and Acceptance of End-of-Life Care in Gynecologic Cancer Patients. Int J Gynecol Cancer. 2017 05; 27(4):838-846.
    View in: PubMed
    Score: 0.037
  19. End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. J Clin Oncol. 2017 Jun 01; 35(16):1829-1835.
    View in: PubMed
    Score: 0.037
  20. Does death anxiety affect end-of-life care discussions? Int J Gynecol Cancer. 2014 Oct; 24(8):1521-6.
    View in: PubMed
    Score: 0.031
  21. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014 Sep; 134(3):546-51.
    View in: PubMed
    Score: 0.030
  22. Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer. 2014 Jul; 24(6):1077-84.
    View in: PubMed
    Score: 0.030
  23. Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: a feasibility study. Gynecol Oncol. 2014 Jan; 132(1):149-53.
    View in: PubMed
    Score: 0.029
  24. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8.
    View in: PubMed
    Score: 0.028
  25. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol. 2013 May; 129(2):304-9.
    View in: PubMed
    Score: 0.028
  26. Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter? Int J Gynecol Cancer. 2009 Aug; 19(6):1107-12.
    View in: PubMed
    Score: 0.022
  27. Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009 Mar; 200(3):288.e1-8.
    View in: PubMed
    Score: 0.021
  28. Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. Int J Radiat Oncol Biol Phys. 2008 Jan 01; 70(1):118-25.
    View in: PubMed
    Score: 0.019
  29. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol. 2005 Jun; 97(3):840-4.
    View in: PubMed
    Score: 0.016
  30. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):442-8.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.